Search Results

Phase Genomics, Inc. today announced $1.5MM in new funding from the Bill & Melinda Gates Foundation to fuel a new antimicrobial discovery platform.

Dovetail Genomics, a pioneering leader in the development of genomic solutions, announced a new strategic partnership with Australian Genome Research Facility.

Dovetail Genomics announces the Dovetail® AssemblyLink™ Assay, a transformative genomics tool designed to redefine the standards of speed and quality in genomic assembly.

Phase Genomics, Inc., a global innovator for industry-leading genomic solutions, today announced the presentation of new data from the proximity ligation sequencing-based OncoTerra cytogenomics platform on the leading-edge AVITI next-generation sequencing system.

Foundation Medicine, Inc., announced that it has formed a collaboration with Repare Therapeutics, a leading clinical-stage precision oncology company, to provide prospective genomic profiling to patients in Repare’s ongoing Phase I/Ib MYTHIC study of lunresertib alone or in combinations in genomically-defined patient populations.

Reveal Genomics ® HER2DX ® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer.

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on revolutionizing medicine with CRISPR-based therapies, announced long-term data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002.

Phase Genomics, Inc., a global provider of industry-leading genomic solutions, has been awarded the “Metagenomics Innovation Of The Year” distinction for 2023 in the third annual BioTech Breakthrough Awards program.